Enoxaparin Protocol After Tenecteplase for STEMI

Primary Recommendation

• The American College of Cardiology (ACC) recommends that, in patients younger than 75 years with normal renal function who receive tenecteplase for STEMI, enoxaparin should be given as a 30 mg intravenous bolus followed by 1.0 mg/kg subcutaneously every 12 hours until hospital discharge (maximum 8 days). This regimen provides a superior reduction in death and reinfarction compared with unfractionated heparin. [Class I, Level A] 1

Dosing for Patients < 75 Years with Normal Renal Function

• Initial dose: 30 mg enoxaparin IV bolus administered immediately with or after tenecteplase. [Class I, Level A] 1
• Maintenance dose: 1.0 mg/kg enoxaparin subcutaneously every 12 hours, beginning within 15 minutes of the IV bolus. [Class I, Level A] 1
• Duration: Continue the regimen throughout the index hospitalization, up to 8 days or until definitive revascularization is performed. [Class I, Level A] 1

Age‑Based Modification (≥ 75 Years)

• Enoxaparin must not be used as an alternative to unfractionated heparin in patients aged ≥ 75 years receiving fibrinolytic therapy (Class III, contraindicated). [Level A] 1
• If enoxaparin is unavoidable in this age group, the 30 mg IV bolus should be omitted and the subcutaneous dose reduced to 0.75 mg/kg every 12 hours. [Expert opinion] 2
• Rationale: Pre‑hospital administration of enoxaparin in patients ≥ 75 years was associated with a significant increase in intracranial hemorrhage. [Class III] 2

Renal Function Adjustments

• Significant renal dysfunction (serum creatinine > 2.5 mg/dL in men or > 2.0 mg/dL in women) is a contraindication to enoxaparin (Class III); unfractionated heparin should be used instead. [Level A] 1
• Moderate renal impairment (creatinine clearance < 30 mL/min) requires dose reduction of enoxaparin to 1.0 mg/kg subcutaneously every 24 hours (the 30 mg IV bolus may be retained if the patient is < 75 years). [Expert opinion] 1

Unfractionated Heparin (UFH) as Alternative

• UFH is preferred over enoxaparin in:
  
  • Patients ≥ 75 years old, [Class III] 1
  • Patients with significant renal dysfunction, [Class III] 1
  • Situations where urgent percutaneous coronary intervention (PCI) is anticipated and switching anticoagulants would be undesirable. [Expert opinion] 1
• UFH dosing with tenecteplase:
  
  • Initial bolus = 60 U/kg IV (maximum 4,000 U). [Class I, Level A] 3
  • Maintenance infusion = 12 U/kg/h (maximum 1,000 U/h for patients > 70 kg). [Class I, Level A] 3
  • Target activated partial thromboplastin time (aPTT) = 1.5–2.0 × control (≈ 50–70 seconds). [Class I, Level A] 3
• Monitoring requirements for UFH:
  
  • aPTT checks at 3, 6, 12, and 24 hours after initiation, and 4–6 hours after any dose adjustment. [Class I, Level A] 3
  • Daily platelet count to detect heparin‑induced thrombocytopenia (HIT). [Class I, Level A] 3

Antiplatelet Therapy (Dual Antiplatelet Therapy)

• Aspirin: loading dose 162–325 mg, then 75–162 mg daily indefinitely. [Class I, Level A] 1
• P2Y12 inhibitor: administered according to contemporary STEMI guidelines (e.g., clopidogrel, prasugrel, or ticagrelor). [Class I, Level A] 1

Glycoprotein IIb/IIIa Inhibitor Considerations

• When a GP IIb/IIIa inhibitor is planned with UFH, reduce the UFH bolus to 50–70 U/kg and target an activated clotting time (ACT) of 200–250 seconds (instead of the standard 60 U/kg and ACT 250–300 seconds). [Expert opinion] 2
• Combination of enoxaparin with GP IIb/IIIa inhibitors (e.g., abciximab) has been associated with increased bleeding in the ASSENT‑3 trial. [Class III, Level B] 2

Heparin‑Induced Thrombocytopenia (HIT) Management

• Preferred alternative anticoagulant: bivalirudin 0.25 mg/kg IV bolus, then 0.5 mg/kg/h for 12 hours, followed by 0.25 mg/kg/h for an additional 36 hours. [Class IIa, Level B] 3
• Monitoring: reduce the bivalirudin infusion rate if the aPTT exceeds 75 seconds within the first 12 hours. [Class IIa, Level B] 3

PCI‑Related Anticoagulation Guidance

• Patients already on enoxaparin should continue enoxaparin during urgent PCI; switching to UFH is not recommended. [Class I, Level A] 3
• Patients on UFH should receive an additional UFH bolus to achieve a target ACT of 250–350 seconds (or 200–250 seconds when a GP IIb/IIIa inhibitor is used). [Class I, Level A] 3
• High‑risk patients (e.g., large anterior MI, atrial fibrillation, known left‑ventricular thrombus) may require anticoagulation beyond the standard 48‑hour minimum, extending for the duration of the high‑risk period. [Class IIa, Level B] 3

STEMI Heparin Protocol

Introduction to STEMI Heparin Management

• The American College of Cardiology recommends administering unfractionated heparin (UFH) to STEMI patients, with dosing depending on the reperfusion strategy, such as fibrinolytic therapy or primary PCI, to achieve optimal anticoagulation 4, 5

Fibrinolytic Therapy Strategy

• For STEMI patients receiving fibrinolytic therapy, the American College of Cardiology suggests an initial UFH dose of 60 U/kg IV bolus (maximum 4,000 U) followed by 12 U/kg/hour infusion (maximum 1,000 U/hour), adjusted to maintain aPTT at 1.5-2.0 times control (approximately 50-70 seconds) 4, 6
• The American College of Cardiology recommends monitoring aPTT at 3, 6, 12, and 24 hours after initiation, then rechecking 4-6 hours after any dose adjustment, and daily monitoring of platelet counts to detect heparin-induced thrombocytopenia 4, 5, 7
• The American College of Cardiology advises continuing anticoagulation for a minimum of 48 hours, preferably for the duration of hospitalization up to 8 days, or until revascularization if performed 5, 7

Primary PCI Strategy

• For STEMI patients undergoing primary PCI, the American College of Cardiology recommends a UFH dose of 70-100 U/kg IV bolus (maximum 5,000 U) when used alone, or 60 U/kg IV bolus (maximum 4,000 U) when administered with glycoprotein IIb/IIIa inhibitors 5
• The American College of Cardiology suggests targeting an activated clotting time (ACT) of 250-350 seconds when UFH is used alone, and 200-250 seconds when used with GP IIb/IIIa inhibitors 5, 7

Alternative: Low-Molecular-Weight Heparin (LMWH)

• For STEMI patients <75 years old without significant renal dysfunction, the American College of Cardiology recommends enoxaparin as an acceptable alternative to UFH, with a dose of 30 mg IV bolus followed by 1.0 mg/kg subcutaneous every 12 hours 4, 8, 5, 7
• The American College of Cardiology advises against using LMWH in patients ≥75 years receiving fibrinolytic therapy (Class III recommendation) and in patients with significant renal dysfunction (Class III recommendation) 4, 9, 8

Special Populations

• For STEMI patients with heparin-induced thrombocytopenia, the American College of Cardiology recommends using bivalirudin as an alternative, with a dose of 0.25 mg/kg bolus followed by 0.5 mg/kg/hour for 12 hours, then 0.25 mg/kg/hour for 36 hours 6, 9, 7

Critical Pitfalls to Avoid

• The American College of Cardiology warns against failing to cap the bolus dose, inadequate aPTT monitoring, switching between UFH and LMWH, and discontinuing heparin prematurely in high-risk patients, as these actions can increase the risk of complications 4, 5, 7, 10

Anticoagulation Strategies for STEMI Patients Undergoing Primary PCI and Fibrinolysis

1. Primary PCI – Unfractionated Heparin (UFH)

• Initial bolus: 70 – 100 U/kg IV (maximum 5,000 U) when UFH is used alone; reduce to 60 U/kg IV (maximum 4,000 U) when a glycoprotein IIb/IIIa inhibitor is co‑administered. Target activated clotting time (ACT) 250‑350 s (or 200‑250 s with a GP IIb/IIIa inhibitor). Discontinue UFH immediately after the PCI procedure. [American Heart Association] [11][12]
• Weight‑based example: For a 70‑kg patient the 70‑100 U/kg range yields 4,900‑7,000 U, capped at 5,000 U; with GP IIb/IIIa inhibitor the 60 U/kg dose yields 4,200 U, capped at 4,000 U. [American Heart Association] [11][12]
• Renal function: No UFH bolus dose adjustment is required for renal impairment, but aPTT should be monitored more frequently. [American Heart Association] [11][12]

2. Primary PCI – Low‑Molecular‑Weight Heparin (Enoxaparin)

• Efficacy: Enoxaparin provides superior outcomes versus UFH, reducing all‑cause mortality and major bleeding in patients undergoing primary PCI (meta‑analysis of 23 PCI trials, 30,966 patients). [European Society of Cardiology] 13
• Dosing (standard): 30 mg IV bolus followed by 1 mg/kg subcutaneously every 12 h (contraindicated in patients ≥75 y, Class III). [European Society of Cardiology] 13

3. Primary PCI – Bivalirudin

• Regimen: 0.75 mg/kg IV bolus, then 1.75 mg/kg/h infusion; give an additional 0.3 mg/kg bolus if needed. Reduce infusion to 1 mg/kg/h when creatinine clearance <30 mL/min. [American Heart Association] [11][12]
• Bleeding risk: Preferred over UFH + GP IIb/IIIa inhibitors in patients at high bleeding risk (Class IIa). [American Heart Association] [11][12]
• Evidence: HORIZONS‑AMI trial showed a 40 % reduction in major bleeding and a 1 % absolute reduction in 30‑day mortality, albeit with a higher rate of acute stent thrombosis. [European Society of Cardiology] 14

4. Anticoagulation After Fibrinolytic Therapy (When Primary PCI Unavailable)

• UFH protocol: Initial bolus 60 U/kg IV (max 4,000 U) followed by continuous infusion 12 U/kg/h (max 1,000 U/h). Target aPTT 1.5‑2.0 × control (≈50‑70 s). Continue for at least 48 h, preferably through hospitalization up to 8 days. [American Heart Association] [11][12]

5. Special Populations

5.1 Heparin‑Induced Thrombocytopenia (HIT)

• Preferred anticoagulant: Bivalirudin is recommended for STEMI patients with HIT. [European Society of Cardiology] 13

5.2 High Bleeding‑Risk Patients

• Anticoagulant choice: Prefer bivalirudin over UFH + GP IIb/IIIa inhibitors (Class IIa). [American Heart Association] [11][12]
• Access site: Radial arterial access is favored over femoral to further reduce bleeding complications. [European Society of Cardiology] 15

5.3 Renal Impairment (Enoxaparin)

• Contraindications: Creatinine >2.5 mg/dL (men) or >2.0 mg/dL (women) – use UFH instead. [European Society of Cardiology] 13
• Dose modification: For CrCl < 30 mL/min, give 1 mg/kg subcutaneously every 24 h (retain IV bolus only if age < 75 y).

5.4 Fondaparinux

• Recommendation: Fondaparinux is a Class III (contraindicated) anticoagulant for primary PCI because of catheter‑related thrombosis risk. [European Society of Cardiology] [13][16]11

6. Drug Interaction & Dosing Adjustments

• GP IIb/IIIa addition: When a GP IIb/IIIa inhibitor is added to UFH, the UFH dose must be reduced from 70‑100 U/kg to 60 U/kg. [American Heart Association] [11][12]
• Switching anticoagulants: Transitioning between UFH and LMWH during the same episode increases bleeding risk and should be avoided. [European Society of Cardiology] 17

7. Transition to PCI After Fibrinolysis

• ACT verification: Prior to PCI, measure ACT and give an additional UFH bolus as needed to achieve target ACT 250‑350 s (or 200‑250 s with GP IIb/IIIa inhibitor). [American Heart Association] [11][12]

All bullet points are supported by the cited references and reflect the strength of recommendation where indicated.